Boehringer Ingelheim disclosed novel cyclic GMP‑AMP synthase (cGAS) inhibitors designed to blunt innate immune sensing in disorders driven by aberrant interferon signalling. The company’s filing lists candidate chemotypes with potential utility across autoinflammatory interferonopathies, pulmonary fibrosis, metabolic‑associated steatohepatitis and systemic autoimmune disease. cGAS is a cytosolic DNA sensor that activates STING and downstream type I interferon responses; small‑molecule inhibitors aim to temper pathological inflammation. The disclosure signals Boehringer’s continued investment in innate immunity drug discovery and provides medicinal chemistry starting points that could progress to in vivo models and partnerable assets.